The Autoimmune Brain Panel™—commonly known as the Cunningham Panel™—is a specialized neuro-immune test designed to measure autoantibodies and cell-signaling activity associated with PANS, PANDAS, Sydenham chorea, and other neuropsychiatric conditions linked to immune dysregulation. This panel evaluates whether the immune system is producing antibodies that may mistakenly target neuronal tissue, particularly structures involved in movement, behavior, mood, memory, and executive function. These autoantibodies can influence dopamine signaling and activate intracellular pathways, potentially contributing to sudden-onset symptoms such as OCD, anxiety, tics, mood changes, or cognitive decline. The panel includes five biomarkers: Anti-Dopamine Receptor D1 (DRD1) Anti-Dopamine Receptor D2L (DRD2L) Anti-Lysoganglioside GM1 Anti-Tubulin CaM Kinase II (CaMKII) activation Together, these markers help identify immune-mediated disruption of neuronal signaling, a pattern observed in autoimmune neuropsychiatric disorders. While this panel does not diagnose PANS/PANDAS on its own, it offers meaningful supportive evidence when interpreted with clinical symptoms, history of infection, and other immune markers such as ASO and anti-DNase B. Because the reference ranges are derived largely from pediatric controls, interpretation must be done in the context of age, symptoms, and clinical assessment. This panel is performed exclusively by Moleculera Labs, a CLIA-certified laboratory specializing in neuro-immune diagnostics.
Moleculera Labs
Moleculera Labs is a CLIA-certified clinical laboratory specializing in neuro-immune diagnostics, with a focus on conditions where the immune system may disrupt normal brain function. They are best known for developing the Autoimmune Brain Panel™ (formerly the Cunningham Panel™), a proprietary set of tests that measures autoantibodies and neuronal cell-signaling activity associated with PANS, PANDAS, Sydenham chorea, and other infection-triggered or immune-mediated neuropsychiatric disorders.
Located in Oklahoma City, Moleculera Labs works at the intersection of immunology, neurology, and psychiatry—an area often overlooked in traditional diagnostic testing. Their research-driven approach helps clinicians identify immune mechanisms that may contribute to sudden-onset symptoms such as OCD, tics, anxiety, movement abnormalities, behavioral changes, and cognitive decline.
Moleculera’s testing platform evaluates how the immune system interacts with specific neuronal targets, including dopamine receptors (D1, D2L), tubulin, lysoganglioside GM1, and CaMKII activation. By identifying abnormal immune responses against these structures, the laboratory provides clinicians with valuable insight into potential autoimmune or post-infectious involvement in neuropsychiatric symptoms.
In addition to diagnostics, Moleculera Labs collaborates with researchers, physicians, and academic centers to advance understanding of immune-related brain disorders and support personalized treatment approaches. Their work has contributed significantly to the evolving clinical recognition of PANS/PANDAS and related neuro-immune conditions.
Test panels by Moleculera Labs
1 panel offered by this laboratory